Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearside Biomedical, Inc. - Common Stock (NQ:CLSD)

0.7865 +0.0115 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearside Biomedical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Exploring Clearside Biomedical's Earnings Expectations
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Clearside Biomedical: Q4 Earnings Insights
Via Benzinga
Preview: Clearside Biomedical's Earnings
Via Benzinga
Clearside Biomedical: Q3 Earnings Insights
Via Benzinga
Earnings Scheduled For May 14, 2025
Via Benzinga
A Peek at Clearside Biomedical's Future Earnings
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and reduced injection frequency by 84% over 24 weeks, with no serious adverse events... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024
CLSD stock results show that Clearside Biomedical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Is Clearside Biomedical Stock Gaining Today?
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying
Via Benzinga
CLSD Stock Earnings: Clearside Biomedical Misses EPS, Misses Revenue for Q1 2024
CLSD stock results show that Clearside Biomedical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
3 Penny Stocks That Insiders Are Buying
Penny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys. 
Via MarketBeat
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
7 Top Stocks Under $7
Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money. 
Via InvestorPlace
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Crash This Month
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.